Laboratory Evaluation of a Dual-Path Platform Assay for Rapid Point-of-Care HIV and Syphilis Testing

Authors:

Abstract
We assessed the laboratory performance of the Chembio Dual Path Platform® HIV-Syphilis rapid immunodiagnostic test and electronic reader for HIV and Treponema pallidum antibody detection in 450 previously characterized serum specimens. For HIV antibody detection, visual and electronic reader sensitivity was 100% and specificity was 98.7%. For Treponema pallidum antibody detection, test sensitivity was 94.7% and specificity was 100.0% for visual interpretation; the electronic reader's sensitivity was 94.7% and specificity was 99.7%.
Funding Information
  • HHS | National Institutes of Health (5R01AI099727)

This publication has 13 references indexed in Scilit: